Your browser doesn't support javascript.
loading
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).
Meertens, Marinda; Muntinghe-Wagenaar, M Benthe; Sikkema, Barend J; Lopez-Yurda, Marta; Retèl, Valesca P; Paats, Marthe S; Ter Heine, Rob; Schuuring, Ed; Timens, Wim; Touw, Daan J; van Boven, Job F M; de Langen, Adrianus J; Hashemi, Sayed M S; Hendriks, Lizza E L; Croes, Sander; van den Heuvel, Michel M; Dingemans, Anne-Marie C; Mathijssen, Ron H J; Smit, Egbert F; Huitema, Alwin D R; Steeghs, Neeltje; van der Wekken, Anthonie J.
Afiliación
  • Meertens M; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Muntinghe-Wagenaar MB; Department of Pulmonology and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
  • Sikkema BJ; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.
  • Lopez-Yurda M; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Retèl VP; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Paats MS; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.
  • Ter Heine R; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands.
  • Schuuring E; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
  • Timens W; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
  • Touw DJ; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
  • van Boven JFM; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
  • de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
  • Hashemi SMS; Department of Pulmonary Medicine, Amsterdam University Medical Center, VU University Medical Center, Amsterdam, Netherlands.
  • Hendriks LEL; Department of Respiratory Medicine, Maastricht University Medical Center, GROW School for Oncology and Reproduction, Maastricht, Netherlands.
  • Croes S; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, CARIM School for Cardiovascular disease, Maastricht, Netherlands.
  • van den Heuvel MM; Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
  • Dingemans AC; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.
  • Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.
  • Smit EF; Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands.
  • Huitema ADR; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Steeghs N; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands.
  • van der Wekken AJ; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Front Oncol ; 13: 1136221, 2023.
Article en En | MEDLINE | ID: mdl-36969063
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Qualitative_research Aspecto: Patient_preference Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Qualitative_research Aspecto: Patient_preference Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza